Revenue Surged 36%; Profit Collapsed 39%. The Gap Explains Why Guidance Is Gone.
A quarter where the headline numbers diverge wildly from organic profit. Strip out the accounting and the one-off hit, and the story shifts from growth to execution risk — and why management won't commit to the rest of the year.
₹6.8 Cr
-39.3% YoY
₹9.8 Cr
-18% YoY (ex-IndAS adj ~₹1.8–2 Cr)
₹33 Cr
+39% YoY
₹107.2 Cr
+36.1% YoY
On the surface, Royal Orchid's Q1 looks like a growth quarter: revenue up 36%, EBITDA up 39%. But the profit number tells the opposite story. PAT fell 39% YoY to ₹6.8 Cr despite revenue surging and EBITDA expanding. Even adjusting for IndAS accounting (~₹1.8–2 Cr drag), organic PAT is down 18% YoY. The gap between headline growth and profit collapse is where the quarter's truth lives.
Where the profit went
Revenue rose 36% YoY to ₹107 Cr
SupportedDelivered ₹107.2 Cr, +36.1% YoY
EBITDA grew 39% YoY to ~₹33 Cr, margin 30.7%
SupportedOPM 23.7%, EBITDA margin 30.7%; numbers align
Strong top-line momentum; new property ramp explains profit divergence
OverstatedRevenue +36% but PAT -39%. Non-IndAS PAT still down 18% YoY. New 237 rooms contributed only management fees (negligible).
ICONIQA will drive yield improvement and premiumization
ContradictedICONIQA occupancy averaged 70% in Q1 (April 79%, May 60%, June 70%) vs Q4's 80%. Revenue contribution negligible; facing 1,000 new competing keys nearby.
We are at 17–18% ROCE, targeting 20%+ once ICONIQA stabilizes
UnverifiedPAT flat ~₹50 Cr for 3+ years despite 2.5x room growth (4k–5k → 7k+ keys). ROCE figure not independently verified.
The precision that matters: adjusted profit
Peel back the reported number and the picture clarifies. IndAS accounting (~₹1.8–2 Cr non-cash charge related to lease and revenue-share model assets) and a GST rule change (₹2.5 Cr input credit loss) account for ₹4–4.5 Cr of the miss. But even the non-IndAS PAT of ₹9.8 Cr is down 18% YoY versus the implied prior-year adjusted PAT of ~₹12 Cr. Organic profit — the kind a holder can bank on — neither grew nor held flat. It declined. The reason: employee costs jumped to 23% of revenue (from 19–20% historically), ICONIQA is still in gestation, and the new asset-light model (revenue-share, leases) carries higher operating drag than the core portfolio.
Three years back we were at ₹50 Cr PAT, this year also we may end up somewhere there, we've moved from 4,000, 5,000 rooms to 8,000, 10,000 rooms. When does the needle move?
What changed on this call
Guidance withdrawn. Prior call (FY26): 'expect better results after Q1.' This call: no FY27–28 guidance given. War cited, but structural profit headwinds (employee costs, GST, ICONIQA ramp) unresolved.
ICONIQA occupancy miss downgraded. Q4 stated 80%, Q1 actual 70% average (May as low as 60%). Competitive pressure (Fairmont, Hilton, Roswin = 1,000 new keys nearby) underplayed.
Management fee contribution materially lower. All 237 new rooms added in Q1 in managed/franchise model. CFO stated contribution 'very, very negligible' (only fees, not revenue share). Profit uplift deferred.
Asset-light model cost structure clarified. Revenue-share and lease models carry IndAS drag and ongoing interest. Not zero-capex; shifts P&L profile unfavorably vs. core hotels.
Regulatory headwind materialized. GST rule change (rates <₹7,500 now 5% GST without input credit) hit Q1 with ₹2.5 Cr loss. Mitigation unclear.
How the street is reading it
The market's reaction confirmed the miss. On day 1 after the result, the stock fell 1.35%, and the decline held: by day 5 it was off 1.86%, with 89.1% delivery (conviction selling). The stock is now at ₹301.55, down 39% from its all-time high of ₹495 and trading below its 20-day, 50-day, and 200-day moving averages — a clear downtrend. RSI is 40.4 (neutral, not oversold), suggesting the market is repricing rather than panicking.
Ownership tells a steady story: FII holdings rose modestly to 8.57% (+0.03pp), DII remains negligible at 0.91% (+0.04pp), and promoters held flat at 64.06% — no insider capitulation or buying signal. The stock is down 39% from ATH, not from recent highs, implying the drawdown reflects a structural repricing over months, not a single-quarter shock. Institutions are nibbling (FII +0.03pp) but not loading up, consistent with a 'wait and see' posture on execution.
The bull-bear ledger
Bull: Asset-light model and large signed pipeline (50 hotels, 11,000+ rooms over 18–24 months) offer structural revenue upside. Revenue +36% is genuine and driven by ADR strength (JLO portfolio +13.6% YoY to ₹6,233) and occupancy hold (70%), not fantasy.
Bull: EBITDA margin of 30.7% is healthy and expanded 70 bps YoY, signaling operational leverage. Core hotel business (JLO) performing; new brand positioning (Regenta, ICONIQA) is credible.
Bear: PAT flat ~₹50 Cr for 3+ years despite 2.5x room growth is a red flag for capital ROI. This quarter PAT -39% YoY despite revenue +36% suggests asset-light = low-margin.
Bear: ICONIQA underperforming: 70% occupancy vs 80% prior. War impact cited, but 1,000 new competing keys and brand immaturity (7 months old) are real. Revenue contribution negligible; large sunk capex at risk if ramp doesn't inflect.
Bear: Employee cost inflation (19–20% → 23% of revenue) and GST surprise (₹2.5 Cr) represent structural and regulatory headwinds. Management promised stabilization in 1–2 years but offered no concrete action plan.
Bear: Guidance withdrawn. Prior promise ('better results after Q1') broken. Management now cites war scenario and offers no timeline for profit inflection. Credibility grade: C.
Risks, ranked by holder impact
PAT stall despite 2.5x room growth — capital ROI unproven
HighThree years of flat ₹50 Cr PAT while rooms grew from 4k–5k to 7k+ suggests new assets are either capital-intensive, low-margin, or both. This quarter confirms: even ex-IndAS/GST, PAT down 18% YoY. If this persists, asset-light = profit ceiling.
ICONIQA profitability at risk — 70% occupancy, 1,000 new competing keys, large sunk capex
HighICONIQA opened Nov 2025, 7 months old, occupancy already below prior-quarter levels (70% vs 80%) and facing new entrants. If ramp stalls, ₹80–100 Cr capex sits on the balance sheet with limited returns.
Regulatory headwind — GST rule change cost ₹2.5 Cr in Q1; relief timeline unclear
HighOne-off impact in Q1, but if other segments face similar rate regime changes (property tax, labour codes, etc.), drag could recur. Represents ₹10 Cr annual run-rate if unresolved.
Employee cost inflation outpacing revenue — 23% of revenue, no offset plan
MediumNew wage code and increments structural; management promises stabilization in 1–2 years but profit hasn't budged. If cost-cutting doesn't materialize, margins will compress further.
Geopolitical headwind persisting — 50% of Indian inbound via Middle Eastern carriers now zero; duration of conflict unknown
MediumBusiness-hotel segment hit harder in Q1. Domestic leisure offsetting, but ICONIQA and managed portfolio both depend on travel recovery. Risk: ramp delayed 2–3 quarters if conflict extends.
What to watch next
1 · Q2–Q4 organic PAT trend (non-IndAS, ex-GST)
Does PAT inflect or remain flat? Management blamed Q1 on ICONIQA gestation + war + GST + IndAS. If Q2–Q4 shows recovery (even modest), the narrative flips. If profit remains stuck despite EBITDA growth, execution risk is confirmed and guidance withdrawal was justified.
2 · ICONIQA occupancy and ADR pathway into Q2–Q4
War cited as Q1 driver (50% inbound gone, 1,000 new competitor keys). By Q2–Q3, does occupancy recover to 75%+? Does ADR begin stepping up (Year 2 uplift promised)? If not, the ₹85 Cr breakeven target is at risk and the hotel becomes a multi-year drag.
3 · Signed pipeline opening cadence and margin contribution
Management guides 50+ hotels, 11,000+ keys over next 18–24 months. If most are in managed (negligible revenue-share) or asset-light models, profit uplift will be further delayed. Watch: what % of new rooms are JLO (owned/leased, higher margin) vs. managed (low margin)?
The debate
The single number to track
Non-IndAS PAT (adjusted for one-off items). Reported PAT is too noisy (IndAS, GST, depreciation). Non-IndAS PAT of ₹9.8 Cr this quarter (down 18% YoY vs ₹12 Cr prior) is the organic profit. By Q4 FY27, watch if this metric turns positive YoY. If it doesn't, the asset-light thesis is broken. If it does, the rebound has credibility and the stock deserves a re-rate.
Royal Orchid's Q1 is a steady-state quarter masquerading as a growth miss. Revenue growth is real (36%), EBITDA is healthy (30.7% margin), and the signed pipeline is large (11,000+ rooms). But profit — the ultimate measure — fell, and even adjusting for one-offs, organic PAT is down year-on-year. The company missed implicit guidance (profit recovery after Q1 didn't happen), withdrew forward guidance (citing war), and is now relying on ICONIQA to be the lever. ICONIQA is 7 months old and already below occupancy targets, facing new competition and dealing with inbound travel disruption.
Management is not mendacious, but it is cautious — and for good reason. Three years of room growth without profit leverage is a legitimate concern. The path back to credibility is concrete: organic PAT inflection by year-end FY27, ICONIQA occupancy north of 75%, and proof that the signed pipeline lifts margins, not just revenue. For now, it's a Hold. The stock is down 39% from ATH and trades below all key averages; that repricing is fair. The next move depends on execution, not multiple expansion.
Revenue growth masked by profit decline; execution risk remains high
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Missed implicit Q1 profit recovery. Blamed external (war, GST), structural (ICONIQA), and accounting (IndAS) factors. Non-IndAS PAT still down ~18% YoY.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Revenue momentum (36% YoY) is genuine, driven by asset-light expansion and ICONIQA. But PAT collapsed 39% YoY and remains flat vs three years ago despite 2.5x room growth—a red flag for execution risk. Management has blamed IndAS, GST, and ICONIQA gestation, but even adjusting for these, profit hasn't inflected. Large signed pipeline (50 hotels, 11k rooms) offers structural upside, but credibility hinges on delivering profitable scale by year-end.
₹107.2 Cr
Revenue · +36.1% YoY₹6.8 Cr
Reported PAT · −39.3% YoYCompressing
Margins · vs guidance: ContradictedDid the claims hold up?
Revenue rose 36% YoY to ₹107 Cr
METDelivered result confirms ₹107.2 Cr, +36.1% YoY
EBITDA grew 39% YoY to ~₹33 Cr, margin 30.7%
METOPM reported 23.7%, consistent with EBITDA growth stated; margin expansion modest
Net profit declined to ₹6.4 Cr vs ₹10.9 Cr prior year
METDelivered ₹6.8 Cr vs implied prior ₹11.2 Cr (YoY -39.3%)
Strong top line momentum; new properties ramp-up explained profit divergence
OVERSTATEDRevenue +36% but PAT -39%. Management blamed IndAS (9.8 Cr non-IndAS basis), GST loss ₹2.5 Cr, ICONIQA gestation, higher financial costs. Even ex-IndAS, PAT down ~18% YoY.
ICONIQA will drive yield improvement and premiumization
MISSICONIQA occupancy averaged 70% in Q1 (April 79%, May 60%, June 70%) vs Q4 80%. Revenue contribution negligible this quarter. ADR guidance for later years speculative.
We are at 17-18% ROCE, targeting 20%+ once ICONIQA stabilizes
UnverifiedROCE figure not independently verified. PAT stalled 3+ years at ~₹50 Cr despite 2.5x room growth suggests capital deployment returns are unproven.
Earnings quality
What changed since the last call
PAT guidance withdrawn
WithdrawnPrior call (FY26): 'expect better position after Q1.' This call: no guidance given, citing war scenario. Analysts expect profit inflection by FY28 but no timeline committed.
ICONIQA occupancy miss
DowngradeQ4 stated 80%, April-May expected 80%. Actual Q1 average 70%. War impact and Q1 seasonality blamed. Revenue contribution negligible this quarter vs earlier optimism.
Management fee business contribution lower than hoped
Downgrade237 new rooms added in Q1, all in managed/franchisee model. CFO stated contribution 'very, very negligible' since only management fees earned. Bulk of growth from JLO hotels (owned/leased).
Asset-light model cost structure clarified
NewPrior: asset-light was zero-capex. Now: revenue-share and lease models carry upfront IndAS costs and ongoing interest. Management flagged shift in P&L profile as model diversified.
Regulatory headwind materialized
NewGST rule change (rates <₹7,500 now 5% GST without input credit) hit Q1 with ₹2.5 Cr loss. Mitigation status unclear; represents tail risk.
The Q&A
Analysts—particularly Rahul Bangadia and Harleen Kaur—pressed hard on the PAT stall (three years at ~₹50 Cr despite 2.5x room growth), the 39% PAT decline this quarter despite 36% revenue growth, and employee cost inflation. Management held firm on 'churning stage' narrative and blamed external shocks (war, GST) + accounting (IndAS) + ICONIQA gestation. Offered no concrete profit inflection timeline. Analysts remained skeptical; several questions deferred or hedged.
ICONIQA premiumization strategy — Anubhav Jain
AnsweredArjun outlined brand family (Z Regenta value, Royal Orchid mid-market, ICONIQA upper upscale). Upgrading ~1,000 five-star keys for higher ADRs. Using ICONIQA selectively on new palaces/collections to enable premium pricing.
Revenue growth attribution — Surbhi Mishra
AnsweredAmit: new 237 rooms negligible (management fees only). Bulk from JLO hotels (owned/leased). JLO occupancy 70%, managed 60.8%. JLO ADR ₹6,233 vs ₹5,488 prior (+13.6%); managed ₹4,300 vs ₹4,031.
Sustainable growth rate guidance — Surbhi Mishra
PartialAmit: 7,000 rooms current, 11,000+ signed for next 12-24 months. Most in managed model (negligible revenue), few in revenue-share. JLO will see 'substantial growth' but exact figure hard to quantify for 3 years out.
Profit inflection timeline — Rahul Bangadia
PartialAmit & Keshav: ROCE 17-18%, targeting 20%+. Churning stage, capital deployed intelligently. Once ICONIQA stabilizes and new properties mature, profit growth will follow. 'Short while longer,' corner about to turn. Acknowledged FY26 saw large revenue ramp + IndAS/GST headwinds.
EBITDA vs. PAT divergence — Harleen Kaur
AnsweredAmit: Investors should look at non-IndAS numbers (9.8 Cr this quarter vs 12 Cr prior, still down ~18%). That shows true business economics. IndAS accounting and depreciation account for the divergence.
ICONIQA occupancy decline — Renuka Sivasankar
AnsweredArjun: Q3-Q4 are best for business hotels, Q1 is lowest. War hit inbound travel (50% via three Middle Eastern carriers, now zero). April 79%, May 60%, June 70%. Q4 80%. August hit by rain.
ICONIQA breakeven target and upside — Rahul Bangadia
AnsweredAmit: ₹85 Cr annualized breakeven (PBT). Above that, 50-60-65% incremental flows to PAT (as fixed costs absorbed). Targeting ₹100 Cr revenue. Q2-Q4 business will determine if achievable.
ADR growth and lease lock-in — Rahul Bangadia
PartialArjun: Hotel 7-8 months old. Year 1 settling in, Year 2 ADRs rise, Year 3 keep rising. Missed RFP season, three new competitors nearby (Fairmont, Hilton, Roswin = ~1,000 new keys). Fighting for business. Expecting repeat bookings and long-term contracts forming now.
Employee cost trajectory — Surbhi Mishra
AnsweredKeshav: New wage code this year, annual increments standard. New leases and strengthened management team added costs. Expect stabilization within 1-2 years as revenues grow from expansion. Annualized, cost is 20-23%.
Management fee target timeline — Surbhi Mishra
DodgedKeshav: Vision 2030 exists but no date/number specified. Grew fees ~14% last year. At 7,700 keys, expecting 11,000+ in 24 months. Hampton by Hilton tie-up positive. But given war scenario, no projections given. ₹150 Cr is 2.5-3x current, very large number.
Guidance
No quantified FY27 or FY28 revenue target
LowManagement cites war scenario, withheld projections. Expects revenue growth from 50+ hotel pipeline (11k+ new rooms in 18-24m) but declined to quantify sustainable growth rate.
ICONIQA targeting ₹85-100 Cr annualized revenue
MediumICONIQA aims for ₹85 Cr breakeven PBT (without IndAS). Targeting ₹100 Cr but only 7-8 months old; ADRs expected to rise Year 2-3. Q1 underperformed seasonal expectations.
No quantified margin guidance for FY27-28
LowManagement implies operating leverage from new properties will improve consolidated margins, but no specific EBITDA/PAT margin target given.
EBITDA margin to maintain at ~30% as portfolio matures
MediumQ1 achieved 30.7% EBITDA margin. Management expects moderation to 20-23% employee cost as revenue base grows; implies sustained margin.
Risks the call surfaced
PAT stall and execution risk
HighPAT flat ~₹50 Cr for 3+ years despite 2.5x room growth (4,000-5,000 → 7,000+ keys). Q1 PAT down 39% YoY despite revenue +36%. Suggests ROI on new properties is weak or capital-intensive model is structurally capped.
ICONIQA underperformance
HighICONIQA opened Nov 2025, 7-8 months old. Q1 occupancy averaged 70% (April 79%, May 60%, June 70%) vs. prior guidance of 80% and Q4 actual 80%. War disrupted inbound; three competing hotels (Fairmont 50k, Hilton 170k, Roswin 110k) opened nearby.
Regulatory and tax headwind
HighGST rule change (rates <₹7,500 now 5% without input credit) hit Q1 with ₹2.5 Cr impact (ITC loss). Company unable to carry forward ITC, must write off. Mitigation strategy and government relief timeline unclear.
Geopolitical and sector headwind
MediumWar scenario disrupted 50% of Indian inbound traffic (via three Middle Eastern carriers). ICONIQA occupancy and market bookings hit. Management withheld FY27 guidance citing war uncertainty. Recovery timing unclear.
Employee cost inflation without offset
MediumEmployee cost rose from 19-20% to 23% of revenue over 8 quarters. New wage code, increments, and leased asset overhead driving increases. Core business revenue hasn't grown; increases are structural headwind.
Management
Score 5/10. Defensive. Management excused misses (IndAS, GST, war, ICONIQA gestation) rather than owning execution. Repeatedly hedged when pressed on PAT inflection timeline; used 'churning stage' and 'short while longer' without dates. Weak. PAT flat ~₹50 Cr for 3+ years despite 2.5x room growth. Q1 delivered revenue +36% but PAT -39%, missing implicit recovery guidance. Non-IndAS PAT also down 18% YoY. Track record does not support optimism.
1 · Q2-Q3 FY27
War-related inbound travel recovery; 50-base hotels opening as planned
2 · Q4 FY27
ICONIQA stabilization and occupancy recovery; year 2 ADR uplift expected
3 · H1 FY28
Large pipeline (11k+ rooms) hitting operational capacity; management fee revenue scale
Large signed pipeline (50 hotels, 11k rooms) offers structural upside, but credibility hinges on delivering profitable scale by year-end.
Royal Orchid Hotels: consol PAT falls 39% YoY to ₹6.8 Cr as finance costs triple
PAT -39.3% YoY · revenue +36.11% · margins compressing
₹107.21 Cr
+36.11% YoY
₹6.79 Cr
-39.3% YoY
5.92%
-7.6pp YoY
₹2.34
Royal Orchid Hotels' consolidated PAT fell 39.3% YoY to ₹6.79 Cr (₹6.42 Cr attributable to owners) even as consolidated revenue rose 36.1% YoY to ₹107.21 Cr, against ₹11.19 Cr PAT and ₹78.77 Cr revenue a year ago. Sequentially both lines eased — revenue down 5.3% and PAT down 17.3% from Q4 FY26's ₹113.17 Cr/₹8.22 Cr — a typical post-peak-season pullback for a hotel chain rather than a fresh deterioration. Consolidated EPS was ₹2.34 versus ₹3.99 a year ago. Neither this quarter nor the year-ago quarter carried exceptional items (Q4 FY26 had a ₹2.17 Cr impairment-reversal gain), so the YoY read is on a clean, comparable basis.
Q1 FY-2027 vs prior quarters
The profit decline sits entirely below the operating line. EBITDA margin (EBITDA/total income) was effectively flat at 28.7% versus 28.6% a year ago, and EBITDA itself grew 39.1% YoY to ₹32.93 Cr — broadly consistent with management's prior-call expectation of "revenue and EBITDA growth." The squeeze came from finance costs, which more than tripled YoY to ₹13.22 Cr (from ₹3.94 Cr, +235%), and depreciation & amortisation, up 125% to ₹11.53 Cr (from ₹5.13 Cr) — together erasing the EBITDA gain by the time it reaches PBT. That scale of finance-cost increase sits uneasily against management's own framing last quarter of "modest capex... funded by strong internal cash reserves," making it the one clause of prior commentary this print strains against even as top-line and EBITDA growth held up.
The stock went into the print at ₹313.9, down 3.3% over the past month of trading.
Management provided limited forward-looking guidance due to current market uncertainties, specifically mentioning the geopolitical situation and rising costs. They are committed to improving performance and are on a growth path, expecting to be in a better position to provide guidance after the first quarter. While rev
— This quarter: met
No verifiable consensus PAT estimate for this quarter turned up in search — this is a small-cap with thin formal coverage — though a pre-print MarketsMojo note had already flagged "weak financials and bearish technicals," consistent with the net-margin compression seen here. Standalone PAT fell a milder 21.9% YoY to ₹2.82 Cr on just 9.8% standalone revenue growth (₹52.22 Cr vs ₹47.56 Cr), well below the 36.1% consolidated pace — the topline expansion is concentrated in subsidiaries and managed/revenue-share properties (new launches in Tirupati and Ahmedabad went live during the quarter) rather than the parent's own hotels. Auditors issued a qualified review report on both statements, citing unresolved SEBI/NCLT proceedings over whether erstwhile subsidiary KSDPL should be treated as a subsidiary rather than an associate, with the NCLT matter next heard on 20 August 2026 and the SEBI matter on 13 August 2026. Separately, the board reiterated the record date (28 August 2026) for the FY26 final dividend of ₹2.5/share approved in May; no new dividend accompanied this result. No standalone management press release was available for this filing, so the statement's own notes are the only management commentary on record this quarter.
W1
Finance-cost trajectory — ₹13.22 Cr this quarter (vs ₹3.94 Cr YoY, +235%); watch whether it normalises as new properties season in or stays elevated.
W2
Management said fuller FY27-28 guidance would follow "after the first quarter" per the Q4 FY26 call — watch the Q1 FY27 concall for quantitative targets.
W3
KSDPL SEBI/NCLT proceedings — NCLT hearing 20 August 2026, SEBI matter hearing 13 August 2026 — could affect associate treatment and future consolidated numbers.